ClinicalTrials.gg
CompletedNCT00236093Updated May 9, 2014

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

A Phase 2 interventional study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) in Pain, Cancer and Sickle Cell Anemia, sponsored by Cephalon. Completed at 28 sites in 3 countries. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2014-05-09.

Sponsored by Cephalon (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Allocation
Non-randomized
Ages
3 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 72 studies testing fentanyl in Pain — 4 open to participants now, 4 under way, none of them phase 3. Fentanyl · Pain.

Started
2006
with 8 others
Phase 2
6 of 72
none open now
Registered
2nd of 72
by date
Lead sponsor
2 of 72
Cephalon

Among the 72 studies testing fentanyl in Pain, this one is one of 9 that started in 2006, is one of 6 in phase 2, and was the 2nd registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 72 studies testing fentanyl in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fentanyl

Fentanyl: first FDA approval 1968 (SUBLIMAZE PRESERVATIVE FREE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 3 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing fentanyl in Pain, or all of them as a file.
02

Study summary

The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.

03

Conditions studied

  • Pain
  • Cancer
  • Sickle Cell Anemia
  • Severe Burns

Keywords

  • Sickle Cell
04

Who can participate

Ages eligible
3 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children are included in the study if all of the following criteria are met:

  • The patient completed participation in ACTIQ double blind study in compliance with the protocol
  • Written of the parent or legal guardian and patient assent, when appropriate, is obtained (lack of assent cannot be overturned)
  • The child is aged 3 to under 16 years (at the time of enrollment into the ACTIQ double blind study) and continues to weight at least 15kg
  • The child must continue using ATC opioid therapy for pain associated with cancer, sickle cell disease, or severe burns and be opioid-tolerant. Opioid tolerant patients are defined as patients who have taken at least 1 mg/kg/day or 40mg/day or more of oral morphine (or an equianalgesic dosage of another opioid) or at least 25 mcg/hour of transdermal fentanyl for at least 7 days. (ATC opioid therapy may be administered as patient controlled analgesia [PCA]).
  • The child must be experiencing episodes of BTP (defined as transient flares of pain that require a bolus of medication as treatment) as follows:

    • Patients with cancer must be experiencing an average of at least 1 BTP episode a day
    • Patients with non-cancer related pain must be experiencing an average of 2 BTP episodes a day
  • Girls who are postmenarch or sexually active must have a negative urine pregnancy test before entry into the study, must be using a medically acceptable method of , and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence
  • The child, in the opinion of the investigator, is able to administer ACTIQ treatment effectively (ie, adequately moving the unit around the mouth and sucking not biting the unit)
  • The child may be an inpatient or outpatient

Exclusion criteria

Exclusion Criteria:

Children are excluded from participating in this study if 1 or more of the following criteria are met:

  • The child has pain uncontrolled by therapy, as determined by the investigator, that could adversely impact the safety of the patient or could be compromised by treatment with ACTIQ.
  • The child has known or suspected /allergies or other to any ACTIQ component
  • The child has received monoamine oxidase inhibitors (MAOIs) within 14 days of the first dose of study drug administration
  • The child has moderate to severe oral mucositis
  • The child has a neuromuscular disease, significant renal impairment, or significant hepatic impairment as determined by the investigator
  • The child has any other medical condition or is receiving concomitant medication/therapy that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise data collection
  • The child is receiving any experimental drug/therapy. NOTE: Children may not be participating concurrently in another study when the other study requires experimental drug therapy.
  • The child is receiving any other treatment that, in the opinion of the investigator, could interfere with the pain response
  • A female patient of , is pregnant, or is lactating (any girl becoming pregnant during the study will be withdrawn from the study)
  • The child has, in the opinion of the investigator, a development delay that would interfere with the use of ACTIQ therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
06

What researchers measure

Primary outcomes

  1. The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ treatment in children with pain and BTP who are receiving ATC opioid therapy.

07

Study locations

28 sites
  • Children's Hospital of Arkansas
    Little Rock, Arkansas 72202, United States
  • Childrens Hospital of Orange
    Orange, California 92868, United States
  • Lucille Packard Childresns Hospital
    Palo Alto, California 94304, United States
  • Connecticut Childrens Medical
    Hartford, Connecticut 06106, United States
  • Childrens National Medical Center
    Washington, District of Columbia 20010, United States
  • Nemours Childrens Clinc
    Jacksonville, Florida 32207, United States
  • St. Joseph's Childrens Hopsital
    Tampa, Florida 33660, United States
  • Kapi'olani Medical Center
    Honolulu, Hawaii 96826, United States
  • University Hospitals of Iowa
    Iowa City, Iowa 52242, United States
  • David Center for Childrens Pain and Palliative Care
    Hackensack, New Jersey 07601, United States
  • Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • Children's Hospital at Montefiore
    Bronx, New York 10467, United States
  • Scottish Rite Children's Medical Center
    Syracuse, New York 13210, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Tod Childrens Hospital
    Youngstown, Ohio 44501, United States
  • Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Children's Cancer and Blood Disorders Center
    San Antonio, Texas 78207, United States
  • Methodist Hospital
    San Antonio, Texas 78229, United States
  • Sacred Heart Medical Center
    Spokane, Washington 99204, United States
  • West Virginia Univeristy
    Morgantown, West Virginia 99204, United States
  • Childrens Hospital of Wisconsin
    Milwaukee, Wisconsin 53201, United States
  • Iwk Health Center
    Halifax, Nova Scotia B3J3G9, Canada
  • San Jorge Childrens Medical
    San Juan, 00912, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006 and a primary completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2005
First posted
Oct 12, 2005
Start
Oct 2006
Primary completionActual
Dec 2006
Last update
May 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00236093
Lead sponsor
Cephalon
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Oct 2006
Primary completion
Dec 2006
Last update
May 9, 2014

Study contacts

John Messina
study director · Cephalon
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl

Start the discussion